Study details
Enrolling now
Dupixent and Narrowband UVB for Atopic Dermatitis
Psoriasis Treatment Center of Central New Jersey
NCT IDNCT05285839ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
40
Study length
about 2.7 years
Ages
18+
Locations
1 site in NJ
What this study is about
This trial is testing a treatment with Dupixent combined with narrowband UVB phototherapy to see if it helps people with atopic dermatitis. The treatment involves taking Dupixent, along with light therapy three times per week for a period of time, followed by just Dupixent alone for another period of time.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dupixent
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Dermatology